Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obervation Letter
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Tables
Technology
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF
Symposium - Contact Dermatitis
2012:78:5;569-582
doi: 10.4103/0378-6323.100547

Hand eczema: An update

Chembolli Lakshmi, CR Srinivas
 Department of Dermatology, PSG Hospital and PSGIMSR, Coimbatore, Tamil Nadu, India

Correspondence Address:
Chembolli Lakshmi
Department of Dermatology, PSG Hospitals and PSGIMSR, Coimbatore - 641 004, Tamil Nadu
India
How to cite this article:
Lakshmi C, Srinivas C R. Hand eczema: An update. Indian J Dermatol Venereol Leprol 2012;78:569-582
Copyright: (C)2012 Indian Journal of Dermatology, Venereology, and Leprology

Abstract

Eczema, the commonest disorders afflicting the hands, is also the commonest occupational skin disease (OSD). In the dermatology outpatient departments, only the severe cases are diagnosed since patients rarely report with early hand dermatitis. Mild forms are picked up only during occupational screening. Hand eczema (HE) can evolve into a chronic condition with persistent disease even after avoiding contact with the incriminated allergen / irritant. The important risk factors for hand eczema are atopy (especially the presence of dermatitis), wet work, and contact allergy. The higher prevalence in women as compared to men in most studies is related to environmental factors and is mainly applicable to younger women in their twenties. Preventive measures play a very important role in therapy as they enable the affected individuals to retain their employment and livelihood. This article reviews established preventive and therapeutic options and newer drugs like alitretinoin in hand eczema with a mention on the etiology and morphology. Identifying the etiological factors is of paramount importance as avoiding or minimizing these factors play an important role in treatment.
Keywords: Alitretinoin, barrier creams, emollients, hand eczema treatment, protective gloves

Introduction

Hand eczema (HE) is the most common form of occupational skin disease (OSD). OSDs comprises approximately 40% of occupational disease with variations in different countries related to the degree of industrialization. [1],[2] The hands have been the affected site in 80% of the OSDs. [3] The increased prevalence in women as compared to men is seen in the younger age group. [4] Atopy (endogenous factor), wet work, irritants, friction, and contact allergy (chromate, nickel, fragrance, biocides, and rubber chemicals) are the major risk factors. [5],[6] Ingested allergens may also provoke HE. [7]

HE is localized to the hands, which are important organs of expression, communication, and are necessary for carrying out daily household and work-related activity. Impairment in form or function can result in severe emotional and psychological distress associated with a poor quality of life comparable to diseases with extensive skin involvement. Skin protection measures and topical treatment are effective in the majority and form the mainstay of treatment regardless of any other additional treatment. Systemic therapy results in remission but cannot be continued indefinitely. No classification of hand eczema would be complete without addressing the etiological and morphological factors. There are several classifications of hand eczema, but are confusing including the recent one based on etiology and morphology proposed by Diepgen et al. [8] We propose a simple modified classification, which encompasses the varied clinical presentations based on previous classifications [Table - 1]. [9],[10] The etiology is any one or a combination of the 4 listed in [Table - 1]. Other skin diseases may mimic HE and may prove a diagnostic challenge initially [Figure - 1] and [Figure - 2]. Thus, in our classification, the differential diagnoses are also included since they closely mimic hand eczema and can be differentiated only by relevant investigations.

Figure 1: Hand dermatitis in a patient with immunofluorescence-proven bullous pemphigoid
Figure 2: Urticarial plaques over the back in the same patient as in Figure 1
Table 1: Classification and differential diagnoses of hand eczema

Atopic hand dermatitis

A history of atopic dermatitis in childhood is a risk factor for the development of hand eczema in adulthood. [9] A history of mucosal atopy does not pose as much risk as atopic dermatitis.

Irritant dermatitis

Exposure to irritants like wet work, mineral oils, organic solvents, and friction [Figure - 3] are known risk factors, especially in persons with underlying atopic dermatitis. [10]

Figure 3: Frictional hand dermatitis in a power loom worker from Tirupur

Protein contact dermatitis

This presents as chronic or recurrent dermatitis, fingertips are commonly involved. Skin contact with the incriminated proteins (fruits, vegetables, spices, plants, animal proteins, grains, and enzymes) may result in flares characterized by urticarial or vesicular lesions within minutes of contact. Patients may complain of stinging, burning, or itching. Contact reactions to proteins are urticarial and last from 30 minutes to about 3 hours. With repeated exposure, eczema may develop. A preceding urticarial reaction is not always necessary for the development of protein contact dermatitis (PCD). [11],[12] Food handlers, cooks, caterers, and housewives are at risk. It is a type I hypersensitivity reaction mediated by allergen-specific IgE in a sensitized person. The gold standard for diagnosis is skin prick testing with fresh material or commercial reagents. [11],[12] Reactions appear within 20 minutes. The positive control is histamine, and negative control is saline [Figure - 4] and [Figure - 5].

Figure 4: Hand dermatitis in a health care worker was investigated by prick testing (Figure 5)
Figure 5: Positive prick test (Contact urticaria) to glove in a health worker

Allergic contact dermatitis

Allergic contact dermatitis (ACD) diagnosed by patch testing is a known cause of hand eczema. It may be the sole causative factor or may be in combination with irritant dermatitis and/or atopic dermatitis.

The causative allergens commonly detected include nickel, cobalt, fragrance-mix, balsam of Peru, and colophony. [13],[14] Recently, allergy to formaldehyde [15] and methyl dibromo glutaronitrile [16] have been reported to be relevant in HE. In India, ACD to Parthenium hysterophorus may present as hand dermatitis [Figure - 6] and [Figure - 7]. [17]

Figure 6: Hand dermatitis in a parthenium-sensitive patient
Figure 7: Papular lesions over the arm mimicking PRP in the same patient as in Figure 6

The various morphological forms include: [9],[10]

1. Pompholyx type [Figure - 8]

Figure 8: Deep seated vesicles on palms

This is characterized by tense, deep-seated crops of "sago-like" vesicles on palms, and/or palmar aspect and sides of the fingers with recurrences. The lesions are intensely pruritic. The plantar aspects of the feet may also be involved. Secondary infection with the development of pustules and lymphangitis may occur. Atopy is the most important factor [Table - 2]. Irritants like soluble oils can cause pompholyx. Pustular lesions may occur in erythema multiforme and pustular psoriasis mimicking pompholyx. [Figure - 9] and [Figure - 10]

Figure 9: Pustular lesions in pustular psoriasis
Figure 10: Pustular lesions in erythema multiforme
Table 2: Causes of Pompholyx-type of reaction over palms

2. Fissured hand eczema (Synonyms: dermatitis palmaris sicca, housewives′ dermatitis)

This is dry eczema with scaling and fissuring and few hyperkeratotic areas. Exudation does not occur, and pruritus is minimal. Seen in longstanding HE persisting for months to years.

3. Hyperkeratotic hand eczema

There are well-defined hyperkeratotic plaques on the palms and on the palmar aspects of the fingers. There is no scaling or vesicle formation. There is no increased incidence of atopy or psoriasis in this group of patients as compared to the general population. It can involve the plantar aspect of feet and is more common in middle-aged and older men. It may be refractory to treatment.

4. Nummular eczema

These are well-circumscribed circular or oval lesions confined to the dorsum of hands or fingers and characterized by erythema, vesicles, oozing in the acute phase and are intensely pruritic. Hyperkeratosis may occur. This form of eczema frequently gets colonized by S.aureus. Atopy is commonly reported in these patients; similar lesions may occur in atopic eczema.

5. Finger tip eczema; pulpitis [Figure - 11]

This is hyperkeratotic eczema of the fingertips with painful fissures, which may extend to merge with eczema over the palm. Vesicles may occur. When all fingers, especially those of the dominant hand are involved, with aggravation in cold climate, this is possibly a cumulative irritant dermatitis where degreasing agents and trauma play a role. When localized to only the thumb, forefinger and third finger, especially of the dominant hand, occupational dermatitis should be considered (irritant or allergic). The non-dominant hand is involved when vegetables and other items related to cooking are held in this hand (E.g., cutting onions, garlic)

Figure 11: Finger tip eczema

6. Interdigital eczema

Erythema and scaling is seen in the interdigital spaces, rarely vesiculation may occur.

Management

The management of HE shall be discussed under 4 sub titles.

  1. Assessment of severity
  2. Diagnostic (history and investigations); identifying etiological factors
  3. Preventive and protective measures
  4. Treatment

1. Assessment of Severity

The severity of hand eczema can be assessed by various scoring methods. [23],[24],[25],[26],[27]

  1. Osnabrck hand eczema severity index (OHSI) (Range 0-18). [24]
  2. Hand eczema severity index (HECSI) (Range 0-360). [25]
  3. Manu score (Range 0-6480). [26]
  4. Hand eczema score for occupational screenings at the workspace (HEROS) (Range 0-2260). [23],[27]

The description of these scoring systems is beyond the scope of this article, and readers are requested to access the references for detailed reading. Most of the skin scores have been developed for severe HE, except the HEROS, which quantifies an early hand eczema and would be useful in occupational screening.

These scoring systems for quantifying HE are useful in evaluating an outcome of treatment. Manu score has the highest range (0-6480). Itching, which is a subjective symptom, is included in this score. Ideally, subjective symptoms, which may be biased, should be excluded in scoring systems.

Localization of lesion may involve either or in combination the dorsa of hands, palmar aspects of hands, sides of fingers, finger web spaces, finger tips, and wrist.

2. Diagnostic (History and Investigations)

Exposure mapping of allergens and irritants [9]

Contact allergens

  • Chemical constitution of product.
  • Workplace visit

    Occupational exposure to paints, glues, cutting oils.

    Procure allergens for patch testing from manufacturer.

  • Chemical spot tests: Nickel, chromate, and cobalt. [28],[29],[30]
  • Testing for formaldehyde in products.
  • Chemical analysis of product in specialized laboratories.

Irritants:

  • Wet work
  • Contact with detergents, alkaline substances, oil products, cutting oils, organic solvents
  • Glove usage (hours spent with tight-fitting/hours spent with wet hands/number of times hands are washed/number of glove changes) [31]
  • Mechanical (frictional) trauma

Wet Work: Based on German standard, the following can give rise to irritant hand eczema [32]

Wet hands for more than 2 hours daily.

Frequent hand washing > 20 times / day

Wearing tight fitting gloves for more than 2 hours per day.

Investigations [17],[33] [Table - 3] serves as a checklist for exposure assessment and investigations

Table 3: Diagnostic (history and investigations)

1. Patch Testing

1. For allergic contact dermatitis

  • With Indian Standard series (ISS), which is the baseline series. [33]
  • With specific series based on results of baseline series.
  • Specific test series may be suggested based exposure related to occupation (hairdressing, health care workers) and hobbies/leisure/household activities
  • In addition, materials by the patient could be included while testing (skin care products, topical medicaments,gloves, etc.)
  • Strong irritants, corrosive or sensitizing products should not be tested. Patch testing is performed according to the International Contact Dermatitis Research Group (ICDRG) guidelines. Exposure is for 2 days, and readings are to be taken on D 2 and D 3 or D 4 and ideally on D 7 also.

2. For irritant contact dermatitis

Detergents are a common cause for hand eczema in housewives, cleaners, and nurses. 24-hour patch testing with detergent and soap solutions (8% w/v), would help identify the cleanser/detergent producing the least irritation. [34],[35]

2. Prick Testing

  • With standardized allergens [17],[33]
  • Prick test with fresh food stuffs.
  • Procedure - done by standard method with histamine as positive control and saline as negative control. The maximum wheal diameter is measured in mm. Whenever possible, record the late phase reaction (LPR) in mm at 24 hours at the prick tested site. [17]

3. Serum IgE estimation

4. RAST (Radio Allergo Sorbent Test).

5. RPA test (R Nase Protection Assay) [36]

This measures small quantities of RNA obtained from tape stripping of human skin and is very sensitive. The RPA test discriminates between irritant and allergic patch test reactions. Interleukin-4 (IL-4) was found to be increased in allergic but not in irritant reactions.

6. Chemical spot tests: For nickel, chromate, and cobalt

7. Test for formaldehyde in product

3. Preventive and Protective measures

Preventive measures

High risk groups such as those with history of atopic dermatitis, hairdressers, health-care workers, food-handlers, and those working with solvents and cutting oils should be identified and educated. [37] In work-related disease, occupational screening and education reduce the incidence of HE. During occupational screening evaluation, issues related to hazardous chemicals, their attributable risk, and reduction of exposure should be addressed. Pre-employment patch testing of healthy subjects identified culprit allergens in 7% of subjects. [38]

Long hours of wet work, low humidity, and hard water increase the risk for dermatitis. [39]

Hand outs on skin care in HE are advised for all patients. (Refer Appendix I)

Protective measures

At the workplace, skin protection is achieved by [14],[40]

  1. Pre-exposure barrier/protective creams to be used on intact skin before and during work. (o/w emulsions, w/o emulsions, tanning agents (cause hardening and increase resistance to irritants. They are also useful under occlusive gloves to reduce skin maceration), aluminium chlorohydrate, zinc oxide which has a shielding effect, talcum, perfluoropolyethers, chelating agents, quarternium-18, bentonite, uv absorbers.)
  2. Cleansing during and after work with mild skin cleansers [41]
  3. Post-exposure skin care after work with emollients, moisturizers, humectants (glycerol, sorbitol, urea), lipids (complex mixtures of ceramide, fatty acid, cholesterol). [42] It has to be kept in mind that some ingredients like urea in moisturizers may increase skin permeability and enhance penetration of hazardous substances. [43]

Emollients and moisturizers are post-exposure skin products that are advisable on diseased skin; they are the mainstay in the prevention and treatment of HE.

Barrier creams or protective creams are to be used on intact skin and should be used prior to the exposure to the irritant. Rarely, barrier creams may trap allergens, and result in worsening of the dermatitis. Allergy to some component of the barrier cream may also rarely occur.

Greasy creams are helpful in restoring barrier function of skin. Preparations, which are fragrance-free and preservative-free, are preferred. Petrolatum is effective against water-soluble and water-insoluble irritants, it is recommended as a standard substance against which barrier creams are compared. [44] White petrolatum (pet.) is a refined, purified, and hydrogenated derivative from mineral oil, consisting of a complex combination of long-chained aliphatic hydrocarbons. [45] Experimental studies using in vivo techniques have proved that white petrolatum effectively protects the skin from water-soluble skin irritants in moderate concentrations and accelerates barrier recovery. [44],[46]

Alcohol-based disinfectants with or without glycerin are less irritant than soap and water and are preferred. [47]

Protective Gloves

Gloves provide an effective protection against most irritants. [41],[48],[49] No single glove protects against the various causes of dermatitis, and wrong selection of gloves may not only lead to increased chance of injury or aggravation of dermatitis but also reduce efficiency during work. Some glove materials are permeable to certain chemicals and thus do not protect against those exposures. Occlusion, latex sensitivity, and contact allergy to other additives in rubber limits their use.

The standards of protective effect conferred by gloves include the EN standard (European Standard, European committee for Standardization) and the ASTM (American Society of Testing and Materials).

In Europe, gloves for protection (PG- protective gloves) are referred to as Personal Protective Equipment (PPE) and are covered under the PPE Directive 89/686/EEC "Gloves intended for protection." The PPE Directive is a part of European Legislation, which defines essential requirement for the product. [50] Medical gloves (MG) are separately covered under the Council Directive 93/42/EEC for medical devices. [51] In the USA, the American society of testing and materials - (ASTM), F-23 on protective clothing includes standards for gloves. [52] Under the EEC-directive, protective gloves are divided into 3 categories. [51]

  1. Category I: Gloves of simple design - minimal risk
  2. Category II: Gloves for intermediate risk
  3. Category III: Gloves for irreversible / life-threatening risks

Methods for testing the level of protection conferred by protective gloves are given in EN 374 of the EEC Directive. [50] The properties tested include penetration, permeation, biocompatibility, and degradation.

Penetration or leakage is the passage of chemicals through macroscopic holes or pores. Faults in the manufacturing process or in storage are possibly responsible. Storage conditions are most important for medical gloves from natural rubber latex. The EN 374- 2 and ASTM F903 have laid down the regulations for testing of penetrability. [49],[51] The British Standard (BS 3574:1989) also has guidelines for storage.

Permeation is the migration of chemicals through the glove at a molecular level from the outer surface to the inner surface contacting the hand. This includes the processes of sorption, diffusion, and desorption. 3 parameters are measured:

  1. Breakthrough time (BT, min) is defined as the time between the initial application of a test chemical to the time when a specific permeation rate (PR) is achieved (This is a PR of 1 μg/min/ cm 2 - EN standard, or 0.1 μg/min/ cm 2 - ASTM standard.) This standard determines permeation under a laboratory environment and not under real working environment where stretching and rise in temperature transmitted from the occluded skin occurs. This will affect the BT.
  2. Permeation rate (PR) is the mass of chemicals migrating through the material per unit time per unit area (μg/min/cm 2 ).Steady-state permeation (SP) when the permeation rate becomes constant
  3. Protection index (PI) is the protective effect conferred by combination of protective glove / test chemical and is based on the BT measured after constant contact with the chemical.
    1. BT (min) > 10 PI = 1
    2. BT > 30 PI = 2
    3. BT > 60 PI = 3
    4. BT > 120 PI = 4
    5. BT > 240 PI = 5
    6. BT > 480 PI = 6
  4. Degradation relates to the glove material and chemical substance interactions. At present, there is no standard, and manufacturers use different test methods to determine degradation occurring with different chemicals in contact with their glove product.

Other test methods include

Biocompatibility (As health care workers are reporting adverse reactions to latex proteins in gloves and other rubber chemicals) . No complete guidelines available on this as yet for in vivo testing in man or in experimental animals.

Based on the results of the testing for penetration and permeation parameters, different pictograms are marked on each glove. [49] [Table - 4]

Table 4: EN374 - Pictograms[47]

Glove materials

The various materials used to manufacture gloves have been elaborated by Mellstrom and Boman. [46] [Table - 5] lists the various materials suitable for use as protective gloves or medical gloves modified from their classification. [48] Protection is conferred by the type of material, manufacturing processes, additives, etc. The protective effect increases with the thickness of the glove as the BT increases with the thickness of glove materials.

Table 5: Various glove materials for protection and medical use

Newer protective gloves [41] include the:

  1. Semi-permeable gloves: Selective semi-permeable membranes from manufacturers like GoreTex® (W. L. Gore and Associates Inc., www.goretex.com) or Sympatex® (Sympatex TechnologiesInc., www.sympatex.com) allow the transport of water-vapour from inside the medium to outside, but prevent penetration of water from outside. These gloves avoid the damaging effects of occlusion on the barrier properties of healthy skin. [53] However, they do not provide adequate protection against chemicals, and therefore, may be used under a protective glove in situations which entails an exposure to wet work but not chemicals.
  2. "Hypoallergenic gloves" are gloves which are free of vulcanization accelerators.
  3. Rip-up gloves are used for protection against cutting fluids (containing allergens like colophony, monoethanolamine) in the metal industry where gloves are not permitted to be worn on account of the risk from rotating machinery. These easy-tearing gloves may help overcome these problems. However, studies have not been conducted on the protection conferred by them.

Adverse effects of gloves include [41]

  1. The right gloves for the substance(s) to be handled should be selected. Without the manufacturer′s recommendations, the false sense of protection conferred by the gloves would pose a chemical hazard.
  2. Internal contamination with chemicals occur if macroscopic holes or increased permeability is present. Incorrect use, incorrect wearing, removal, and disposal of gloves would still predispose to contamination in the absence of structural defects of the glove.
  3. Occlusion may result in irritant contact dermatitis.
  4. Contact urticaria to latex in gloves (Type I allergy). Legal and preventive measures have brought down the incidence of this condition. [54]
  5. Allergic contact dermatitis. The list of allergens include:
    1. Thiurams (commonest) [55]
    2. Dithiocarbamates, mercaptobenzothiazol, and derivatives [56]
    3. 1,3 - diphenylguanidine causes false positive reactions though it is never used
    4. In Polyvinyl chloride (PVC) gloves, the culprit allergens are bisphenol A, formaldehyde, or benzisothiazolinon. [57]
    5. Natural rubber latex (rarely Type IV hypersensitivity) [58]

Treatment

In the acute stage, it is important to soothe the irritated skin with wet compresses or soaks (saline, aluminium acetate, potassium permanganate solution may be used), and not use occlusive ointments. In the sub-acute stage, creams may be introduced and in the chronic stage, ointments (Soothe the acute with compresses and anoint the chronic with occlusive ointments). Topical treatment with emollients and topical corticosteroids in addition to skin protection measures form the mainstay of therapy. [6],[59],[60],[61],[62],[63]

Elimination diets : Ingested allergens may cause variety of skin and mucocutaneous lesions including perioral dermatitis, gingivostomatitis, pruritis ani related to sites of contact. In addition, systemic contact dermatitis and a flare-up of dermatitis in previously sensitized sites may also occur. Ingestion of nickel in diet may provoke these reactions, and a nickel elimination diet may lead to clinical improvement or clearance of hand eczema. [59] A low cobalt diet is also proposed in some patients. [57]

The rule of the 4 R′s can be applied in the management of hand eczema. [60]

  1. Recognition of the culprit irritant/allergen
  2. Removal of the irritant/allergen
  3. Reduction of skin inflammation
  4. Restoration of the skin barrier

The various treatment modalities are listed in [Table - 6].

Table 6: Therapeutic armamentarium in hand eczema

Emollients and Barrier creams

Following an episode of dermatitis, it takes weeks to months for the skin barrier to be restored. [60] Emollients and moisturizers help to restore the barrier. Sometimes, the demarcation between moisturizers used to restore the barrier and barrier creams, which are used to prevent dermatitis (irritant/contact), is not clear. They may prove harmful to the skin barrier. White petrolatum would be an effective emollient and barrier cream, so would be the topical emollient of choice.

Barrier repair

The concomitant treatment of dermatitis influences the barrier repair. [60] Topical and systemic corticosteroids, retinoids control the inflammation well but have a negative effect on barrier recovery. Topical calcineurin inhibitors allow normal recovery while UV- phototherapy exerts its beneficial effect by skin hardening or accommodation (strengthening the barrier), thus making it less sensitive to irritants and control of ACD even with continued exposure.

Keratolytics used include salicylic acid up to 20%, and urea 5-10%. Urea softens the horny layer, and increases its water-binding and penetration-enhancing capabilities. Occlusion may cause skin irritation and burning. The potential to enhance penetration of noxious chemicals should also be kept in mind.

Topical Steroids

They, along with emollients are the mainstay of therapy. [61]

Potent topical steroids are used daily for about 4 weeks and then tapered to alternate day regimen. [63] Long term intermittent monotherapy with moderately-potent steroid-like mometasone furoate has been found to be effective. [63],[64],[65] Potent steroids are more effective and reduce the risk of recurrences as compared to moderately-potent steroids. [66] The adverse effects of long term topical corticosteroid usage are well-known (skin atrophy, tachyphylaxis, and adrenal suppression). Alternating a moderately-potent topical steroid with a topical calcineurin inhibitor reduces these side effects and clinically found to be effective. Topical tacrolimus is reported to be as effective as mometasone furoate in dyshidrotic palmar eczema, while the efficacy of pimecrolimus is comparable to a mild potent steroid. [67] Hypersensitivity to corticosteroids or other ingredients should be suspected if there is worsening. Patch testing with corticosteroid series would help in confirmation. Wet wrap dressings have been found to be effective in atopic eczema. [68]

Phototherapy improves the skin barrier. Topical psoralen UVA (PUVA) has been found to be superior to phototherapy with UVB [69] although pigmentation may be of concern in Indian patients. PUVA should be considered first for hyperkeratotic eczema as it is relatively safe. Broad and narrow band UVB, PUVA, and UVA1 have been reported to be beneficial.

UVA1 is considered to be less carcinogenic than PUVA and UVB. [70] Moderate to high doses give long remissions. [40 J/cm 2 5 times per week for 3 weeks (~ 600 J/cm 2 ) per treatment cycle. [70]

Topical bexarotene gel, a retinoid used for the treatment of lymphoma, has been reported to be effective although irritation, stinging, burning, and a flare of dermatitis has been reported. [71]

Coal tar-based products are effective in sub-acute and chronic eczema and have an anti-inflammatory, anti-pruritic, and anti-proliferative effect.

Radiotherapy (Grenz rays / superficial X-rays)

Grenz rays are safer than X-rays since penetration is only skin deep. Superficial X-rays was found to be more effective than Grenz rays, possibly due to deeper penetration. [72]

Other rarely tried therapies

When hand dermatitis is combined with hyperhidrosis, aluminium chloride hexahydrate and tap water iontophoresis may be effective; botulinum type A toxin may also be effective. [73]

Systemic Therapy

There are several drugs which are commonly used in treatment. Excepting alitretinoin, most of these drugs are not licensed for the treatment of hand eczema. Alitretinoin is approved in adults for the treatment of HE unresponsive to topical steroids, based on evidence from a larger randomized trial. [74]

Systemic corticosteroids

Oral corticosteroids are used in the short term management of acute hand eczema or during an exacerbation of chronic HE (0.5 - 1 mg/kg/day) with rapid tapering; long term use is not advocated due to their side-effects.

Oral retinoids

Retinoids are vitamin A derivatives which are either endogenous (physiological) or synthetic.

Acitretin, a synthetic retinoid, 40 mg oral daily showed 50% improvement at 4 weeks in a study (n = 14) of patients with hyperkeratotic hand eczema. There was no further improvement at week 8. [75] Combined therapy with other drugs may prove more beneficial.

Alitretinoin (9-cis-retinoic acid)

Isotretinoin is a naturally-occurring retinoid found in the body in small quantities. Alitretinoin is an isomer of isotretinoin (13-cis-retinoic acid) and is an endogenous physical retinoid. Although structurally similar to isotretinoin, sebum secretion is not suppressed significantly, which could explain the lower incidence of mucocutaneous side-effects like dryness, cheilitis, etc. and also the lack of efficacy in acne. [76]

There are 2 families of nuclear receptors associated with retinoids - retinoid acid receptors (RARs) and retinoid X receptors (RXRs). Alitretinoin binds to both RARs and RXRs.

Alitretinoin is currently the only evidence-based therapy for patients with severe chronic hand eczema, unresponsive to potent topical corticosteroids. There are 3 large phase II clinical trials assessing its safety. The first is a large, randomized, multi-centric, placebo controlled, double blind study in 111 dermatology clinics in Europe and Canada. The BACH study (Benefit of Alitretinoin in Chronic Hand Eczema) is currently the largest-controlled trial in hand eczema. [74] The commonest side-effect was headache; other less common side-effects were muco-cutaneous side-effects and dryness, decreased TSH levels and hyper-triglyceridemia. [74] Alitretinoin is a teratogen-like other retinoids, but has a shorter half life (mean t1/2 2-10 hours) than acitretin (mean t1/2 39-96 hours). Contraception is recommended 1 month post-treatment with alitretinoin as compared to 3 years for acitretin. In the BACH study, patients who relapsed within 24 weeks after completion or those who didn′t respond were retreated with alitretinoin 30 mg for 24 weeks, of which, 50% achieved ′clear′ or ′almost clear′ hands. [77] These patients were included in the second trial, which was a double-blind, placebo-controlled, randomized study. [75] The third trial was an open-label, single-fixed dose study in 249 patients. [78]

Cyclosporine

Cyclosporine at 3 mg/kg/day for 6 weeks was reported to be as effective as topical betamethasone dipropionate. [79] It has been studied extensively in the treatment of atopic dermatitis. [80] Very slow tapering over a period of 6 months is recommended. A lack of response beyond 8 weeks should suggest discontinuation of therapy. Blood pressure, serum potassium, and creatinine should be monitored.

Azathioprine

It is an effective steroid-sparing agent and can also be used alone in hand eczema (2 mg/kg/day). Hand eczema seen with parthenium dermatitis responds well to azathioprine. [17] Atopic hand eczema also shows good response. [81] Due to genetic polymorphisms, 11% of the population have intermediate TPMT activity and are predisposed to toxic effects. 1 in 300 people has low or no activity and is susceptible to life-threatening pancytopenia; other frequencies are also reported. [82] Dosage should be advised after checking the TPMT levels.

Methotrexate

Low dose methotrexate (5-20 mg weekly) has been reported to be effective in chronic hand eczema. [83] In an atopic patient with parthenium dermatitis presenting as hand dermatitis, methotrexate has been found to be effective. [17]

Mycophenolate mofetil

Beneficial effects have been reported in a single patient with hand eczema. [84]

The treatment of chronic hand eczema still remains an arduous task since the majority do not derive adequate benefit from the multitude of therapies. Newer superpotent steroids like halometasone monohydrate once-daily for a limited period during the initial phase of chronic-fissured HE should be studied. Cyclosporine and azathioprine are beneficial in HE with an atopic background. Alitretinoin is a new drug licensed for use in severe chronic HE, with good results in a clinical trial, having the side-effects of retinoids, at a lesser degree.

When chronic hand eczema is characterized by combined allergic and irritant contact dermatitis, filaggrin gene mutations may play a role. [85] Identifying the cause and avoiding it could result in complete clearance in a case of ACD; however, in irritant and atopic dermatitis, avoiding the irritant factor is not always feasible.

Lifestyle change is recommended for all patients, avoiding all possible irritants and allergens.

Skin care and personal protection measures should be individualised for each person and his/her environment.

References
1.
Diepgen TL, Coenraads PJ. The epidemiology of occupational contact dermatitis. Int Arch Occup Environ Health 1999;72:496-506.
[Google Scholar]
2.
Lodi A, Mancini LL, Ambonati M, Coassini A, Ravanelli G, Crosti C. Epidemiology of occupational contact dermatitis in North Italian population. Eur J Dermatol 2000;10:128-32.
[Google Scholar]
3.
Turner S, Carder M, van Tongeren M, McNamee R, Lines S, Hussey L, et al. The incidence of occupational skin disease as reported to the Health and Occupation reporting (THOR) network between 2002 and 2005. Br J Dermatol 2007;157:713-22.
[Google Scholar]
4.
Meding B, Lantto R, Lindahl G, Wrangsjo K, Bengtsson B. Occupational skin disease in Sweden - A 12-year follow-up. Contact Dermatitis 2005;53:308-13.
[Google Scholar]
5.
Coenraads PJ, Diepgen TL. Risk of hand eczema in employees with past or present atopic dermatitis. Int Arch Occup Environ Health 1998;71:7-13.
[Google Scholar]
6.
Diepgen TL, Agner T, Aberer W, Berth-Jones J, Cambazard F, Elsner P, et al. Management of chronic hand eczema. Contact Dermatitis 2007;57:203-10.
[Google Scholar]
7.
Jensen CS, Menne T, Lisby S, Kristiansen J, Veien NK. Experimental systemic contact dermatitis from nickel: A dose-response study. Contact Dermatitis 2003;49:124-32.
[Google Scholar]
8.
Diepgen TL, Andersen KE, Brandao FM, Bruze M, Bruynzeel DP, Frosch P, et al. Hand eczema classification: A cross-sectional, multicentre study of the etiology and morphology of hand eczema. Br J Dermatol 2009;160:353-8.
[Google Scholar]
9.
Menne' T, Johansen JD, Sommerlund M, Veien NK, Hand Eczema guideline based on the Danish guidelines for the diagnosis and treatment of hand eczema. Contact Dermatitis 2011;65:3-12.
[Google Scholar]
10.
Berth-Jones J. Eczema, Lichen planus, Prurigo and Erythroderma. In: Burns DA, Breathnach SM, Cox NH, Griffiths CE, editors. Rook's Text Book of Dermatology. 8 th ed. UK: Blackwell Publishing Ltd; 2010.
th ed. UK: Blackwell Publishing Ltd; 2010.'>[Google Scholar]
11.
Amaro C, Goossens A. Immunological, occupational contact urticaria and contact dermatitis from protein. Contact Dermatitis 2008;58:67-75.
[Google Scholar]
12.
Levin C, Warshaw E. Protein contact dermatitis: Allergens, pathogenesis and management. Dermatitis 2008;19:241-51.
[Google Scholar]
13.
Meding B. Epidemiology of hand eczema in an industrial city. Acta Derm Venereol 1990;153(Supp l):1-43.
[Google Scholar]
14.
Heydorn S, Johansen JD, Andersen KE, Bruze M, Svedman C, White I, et al. Fragrance allergy in patients with hand eczema. Contact Dermatitis 2003;48:317-23.
[Google Scholar]
15.
Cronin E. Formaldehyde is a significant allergen in women with hand eczema. Contact Dermatitis 1991;25:276-82.
[Google Scholar]
16.
Zachariae C, Rastogi S, Devantier C, menne T, Johanses J. Methyl dibromo glutaronitrile: Clinical experience and exposure based risk assessment. Contact Dermatitis 2003;48:150-4.
[Google Scholar]
17.
Lakshmi C, Srinivas CR. Parthenium the Terminator: An update. Indian Dermatol Online J 2011 [In press].
[Google Scholar]
18.
Menne T, Hjorth N. Pompholyx-dyshidrotic eczema. Semin Dermatol 1983;2:75-80
[Google Scholar]
19.
Meneghini CL, Angelini G. Contact and microbial allergy in Pompholyx. Contact Dermatitis 1974;5:46-50.
[Google Scholar]
20.
Cronin E. Oral challenge in nickel hypersensitive women with hand eczema. In: Brown SS, Sunderman FW Jr, editors. Nickel Toxicology. New York: Academic Press, 1980. p. 149-55.
[Google Scholar]
21.
Ekelund AG, Moller H. Oral provocation in eczematous contact allergy to neomycin and hydroxyquinolones. Acta Derm Venereol (Stockh) 1969;49:422-6.
[Google Scholar]
22.
Edman B. Palmar eczema: A pathogenic role for acetylsalicylic acid, contraceptives and smoking? Acta Derm Venereol (Stockh) 1988;68:402-7.
[Google Scholar]
23.
WeistenhoferW, Baumeister T, Drexler H, Kutting B. An overview of skin scores used for quantifying hand eczema: A critical update according to the criteria of evidence-based medicine. Br J Dermatol 2010;162:239-50.
[Google Scholar]
24.
Skudlik C, Dulon m, Pohrt U, Appl KC, John SM, Nienhaus A. Osnabruek hand eczema severity index - A study of the interobserver reliability of a scoring system assessing skin disease of the hands, Contact Dermatitis 2006;55:42-7.
[Google Scholar]
25.
Held E, Skoet R, Johansen JD, Agner T. The hand eczema severity Index (HECSI): A scoring system for clinical assessment of hand eczema. A study of inter and intraobserver reliability. BrJ Dermatol 2005;152:302-7.
[Google Scholar]
26.
John SM. Diagnostics in the investigation of occupational disease - I: operationalisation of the clinical findings (Manuscore). In clinical In: Clinical and Experimental Studies of the Diagnostiscs in Occupational Dermatology (John SM, ed). Osnabruek: Universitat Verlag Rasch, 2001; 133-141
[Google Scholar]
27.
Weistenhofer W, Bauneister T, Drexler H, Kutting B. How to quantify skin impairment in primary and secondary prevention? HEROS: a proposal of a hand eczema score for occupational screening.Br J dermatol 2011;164:807-13.
[Google Scholar]
28.
Srinivas CR, Lakshmi C. Occupational Dermatoses, chemical tests, In: Walia RG, Walia AR (eds), IADVL TextBook and Atlas of Dermatology, 3 rd edition, Mumbai, Bhalani publishing house, pp 506-507
[Google Scholar]
29.
Srinivas CR, Sundaram VS, Selvaraj K. Reducing the hexavalent chromium in leather to hypoallergenic trivalent chromium for prevention of leather dermatitis. Indian J Dermatol Venereol Leprol 2007;73:428-9.
[Google Scholar]
30.
Thyssen JP, Menne T, Johansen JD, Liden C, Julander A, Moller P et al. A spot test for detection of cobalt release- early experience and findings. Contact Dermatitis 2010;63:63-9.
[Google Scholar]
31.
Frosch PJ, John SM. Clinical aspects of irritant contact dermatitis. In: Johansen JD, Frosch PJ, Lepoittevin JP, editors. Contact Dermatitis. 5 th ed. Heidelberg: Springer-Verlag; 2011. p. 305-45.
[Google Scholar]
32.
Bundesanstalt fier Arbeitsschut zund Arbectsmedizen TRGS 401, Gefahrdung durch Hawlkintakt-Eramittlung, beurtelung, Massnahomen. Ausgabe 2008. Available from: http://www.de/nn_41278/de. Themen-von-A-Z/Gefahrstoffee/TRGS/ Pdf / TRGS-401. Pdg? [Last accessed on 2011 Dec].
[Google Scholar]
33.
Lakshmi C, Srinivas CR. Type I Hypersensitivity to Parthenium hysterophorus in patients with parthenium dermatitis. Indian J Dermatol Venereol Leprol 2007;73:103-5.
[Google Scholar]
34.
Lakshmi C, Srinivas CR, Anand CV, Mathew A C. Irritancy ranking of 31 cleansers in a 24-hr patch test. Int J Cosm Sci 2008;30:277-83.
[Google Scholar]
35.
Austoria AJ, LakshmiC, Srinivas CR, Anand CV, Mathew AC. Irritancy potential of 17 detergents used commonly by the Indian household. Indian J Dermatol Venereol Leprol 2010;76:249-53.
[Google Scholar]
36.
Morhenn VN, Chang EY, Rheins LA. A noninvasive method for qualifying and distinguishing inflammatory skin reaction. J Am Acad Dermatol 1999;41:687-92.
[Google Scholar]
37.
37. Funke U, Diepgen TL, Fartasch M. Risk-group-related prevention of hand eczema at the workplace. Curr Probl Dermatol 1996;25:123-32.
[Google Scholar]
38.
Milkovic-Kraus S, Marcan J. Can pre-employment patch testing help to prevent occupational contact allergy? Contact Dermatitis 1996;35:226-8.
[Google Scholar]
39.
Warren R, Ertel KD, Bartolo RG, Levine MJ, Bryant PB, Wong LF. The influence of hard water (calcium) and surfactants on irritant contact dermatitis. Contact Dermatitis 1996;35:337-43.
[Google Scholar]
40.
Rietschel RL, Fowler Jr JF. Hand dermatitis due to contactants: Special Considerations. In: Rietschel RL, Fowler Jr JF, editors. Fisher's Contact Dermatitis. 6 th ed. Hamilton: BC Decker Inc; 2008. p. 319-38.
th ed. Hamilton: BC Decker Inc; 2008. p. 319-38.'>[Google Scholar]
41.
Wulfhorst B, Bock M, Skudlik C, Wigger Alberti W, John SM. Prevention of hand eczema: Gloves, Barrier creams and Workers education. ln: Johansen JD, Frosch PJ, Lepoittevin JP editors. Contact Dermatitis 5 th ed. Heidelberg: Springer Verlag; 2011. p. 992-8.
[Google Scholar]
42.
Man MQ, Feingold KR, Elias PM. Exogenous lipids influence permeability barrier recovery in acetone - treated murine skin. Arch Dermatol 1992;129:728-38.
[Google Scholar]
43.
Wohlrab W. The influence of urea on the penetration kinetics of topically applied corticosteroids Acta Derm Venereol (Stockh) 1984;64:233-8.
[Google Scholar]
44.
Wigger-Alberti W, Elsner P. Petrolalum prevents irritation in a human cumulative exposure model in vivo. Dermatology 1997;194:247-50.
[Google Scholar]
45.
45. Loden M. Role of topical emollients and moisturizes in the treatment of dry skin barrier disorders. Am J Clin Dermatol 2003;4:771-88.
[Google Scholar]
46.
46. Ghadially R, Halkier Sorensen L, Elias PM. Effects of petrolalum on stratum corneum structure and function. J Am Acad Dermatol 1992;26:387-96.
[Google Scholar]
47.
47. Pedersen LK, Held E, Johansen JD, Agner T. Less skin irritation from alcohol - based disinfectant than from detergent used for hand disinfection. Br J Dermatol 2003;153:1142-6.
[Google Scholar]
48.
48. Mellstrom GA, Boman A. Protective gloves. In: Chew AL, Maibach HI, editors. Irritant dermatitis. Berlin: Springer; 2006 p. 409-19
[Google Scholar]
49.
49. CEN EN 374-I -III. protective gloves against chemicals and microorganisms. Brussels: Comite European de Normalization; 2003.
[Google Scholar]
50.
50. CEN EN 420-2003. Protective gloves - general requirements and test methods. Brussels: Comite European de Normalization; 2003.
[Google Scholar]
51.
51. MellstrÖm GA, Carlsson B. European Standards on protective gloves. In: MellstrÖm GA, Wahlberg JE, Maibach HI, editors. Protective gloves for occupational use. Boca Raton, FL: CRC press; 1994. p. 39-43.
[Google Scholar]
52.
52. Henry III NW. US rules, regulations and standards for protective gloves for occupational use. In: Boman A, Estlander T, Wahlberg JE, Maibach HI, editors. Protective gloves for occupational use. 2 nd ed. Boca Raton FL: CRC Press; 2005. P. 35-41.
[Google Scholar]
53.
53. Wulfhorst B, Schwanitz HJ, Bock M. Optimizing skin protection with semipermeable gloves. Dermatitis 2004;15:184-91.
[Google Scholar]
54.
54. Allmers H, Schmengler J, John SM. Decreasing incidence of occupational contact urticaria caused by natural rubber latex allergy in German healthcare workers. J Allergy Clin Immunol 2004;114:347-51.
[Google Scholar]
55.
55. Bhargava K, White IR, White JML. Thiuram patch test positivity 1980-2006: Incidence is now falling. Contact Dermatitis 2009;60:222-3.
[Google Scholar]
56.
56. Geier J, Lessman H, Uter W, Schmuch A. Occupational rubber glove allergy: Results of the Information Network of Departments of Dermatology (IVDK), 1995 to 2001. Contact Dermatitis 2003;48:39-44.
[Google Scholar]
57.
57. Aalto-Korte K, Ackermann I, Henrike-Eckerman ML, Valimaa J, Reinikka-Railo H, Leppanen E, et al. 1,2-benzisothiazolin-3-one in disposable polyvinyl chloride gloves for medical use. Contact Dermatitis 2007;57:365-70.
[Google Scholar]
58.
58. Sommer S, Wilkinson SM, Beck MH, English JS, Gawkrodger DJ, Green C. Type IV hypersensitivity reactions to natural rubber latex: Results of a multicentre study. Br J Dermatol 2002;146:114-7.
[Google Scholar]
59.
59. Lofgren SM, Warshaw EM. Dyshidrosis: Epidemiology, clinical characteristics, and therapy: Dermatitis 2006;17:165-81.
[Google Scholar]
60.
60. Antonov D, Schliemann S, Elsner P. Therapy and Rehabilitation of Allergic and Irritant Contact Dermatitis. ln: Johansen JD, Frosch PJ, Lepoittevin JP, editors. Contact Dermatitis 5 th ed. Heidelberg: Springer - Verlag; 2011. p. 963-79.
[Google Scholar]
61.
61. English J, Aldridge R, Gawkrodger DJ, Williams J. Consensus statement on the management of chronic hand eczema. Clin Experiment Dermatol 2009;34:761-9.
[Google Scholar]
62.
62. Bissonette R, Diepgen TL, Elsner P, English J, Graham-Brown, Homey B, et al. Redefining treatment options in chronic hand eczema (CHE). J Eur Acad Dermatol Venereol 2010;24(Suppl 3):1-20
[Google Scholar]
63.
63. Diepgen TL, Elsner P, Schliemann S, Fartasch M, Kollner A, Skudlik C, et al. Guideline on the management of hand eczema. J Dtsch Dermatol Ges 2009;7:S1-16.
[Google Scholar]
64.
64. Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hordinsky MK, et al. Guidelines/ Outcomes Committee. Guidelines of care for the use of topical glucocorticoids. J Am Acad Dermatol 1996;35:615-9.
[Google Scholar]
65.
65. Veien NK, Olholm Larsen P, Thestrup-Pederson K, Schou G. Long-term intermittent treatment of chronic hand eczema with mometasone furoate . Br J Dermatol 1999;140:882-6.
[Google Scholar]
66.
66. Moller H, Svartholm H, Dahl G. Intermittent maintenance therapy in chronic hand eczema with clobetasol propionate and fluprednilen acetate. Curr Med Res Opin 1983;8:640-4.
[Google Scholar]
67.
67. Schnopp C, Remling R, Mohrenschlager M, Weigl L, Ring J, Abeck D. Topical tacrolimus (FK506) and mometasone furoate in treatment of dyshidrotic palmar eczema: A randomized, observer-blinded trial. J Am Acad Dermatol 2002;46:73-7.
[Google Scholar]
68.
68. Devillers AC, Orange AP. Efficacy and safety of 'wet-wrap" dressings as an intervention treatment in children with severe and /or refractory atopic dermatitis: A critical review of the literature. Br J Dermatol 2006;154:579-85.
[Google Scholar]
69.
69. Rosen K, Mobacken H, Swanbeck G. Chronic eczematous dermatitis of the hands, a comparison of PUVA and UVB treatment. Acta Derm Venereol 1987;67:48-54.
[Google Scholar]
70.
70. Polderman MC, Govaert JC, le Cessie S, Pavel S. A double blind placebo controlled trial of UV-A1 in the treatment of dyshidrotic eczema. Clin Exp Dermatol 2003;28:584-7.
[Google Scholar]
71.
71. Hanifin JM, Stevens V, Sheth P, Breneman D. Novel treatment of chronic severe hand dermatitis with bexarotene gel. Br J Dermatol 2004;150:545-53.
[Google Scholar]
72.
72. Fairris GM, Jones DH, Mack DP, Rowell NR. Conventional superficial X-ray versus Grenz ray therapy in the treatment of constitutional eczema of the hands. Br J Dermatol 1985;112:339-41.
[Google Scholar]
73.
73. Wollina U. Pompholyx: What's new? Expert Opin Investig Drugs 2008;17:897-9004.
[Google Scholar]
74.
74. Ruzicka T, Lynde CW, Jemec GB, Diepgen T, Berth-Jones J, Coenraads PJ, et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: Results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol 2008;158:808-17.
[Google Scholar]
75.
75. Thestrup-Pederson K, Andersen KE, Menne T, Veien NK. Treatment of hyperkeratotic dermatitis of the palms (eczema keratoticum) with oral acitretin. A single-blind placebo-controlled study. Acta Derm Venereol 2001;81:353-5
[Google Scholar]
76.
76. Geiger JM, Hommel L, Hartms M, Saurat JH. Oral 13-cis-retinoic acid is superior to 9-cis retinoic acid in sebo suppression in human beings. J Am Acad Dermatol 1996;34:513-5.
[Google Scholar]
77.
77. Bissonnette R, Worm M, Gerlach B, Guenther L, Cambazard F, Ruzicka T, et al. Successful retreatment with alitretinoin in patients with relapsed chronic hand eczema. Br J Dermatol 2010;162:420-6.
[Google Scholar]
78.
78. Diepgen T, Maleszka R, Bissonnette R, Augustin M, Harsch M, Brown T. An open label study of the safety and efficacy of alitretinoin in severe refractory chronic hand eczema. Poster presented at European Academy of Dermatology and Venereology (EADV): 281. May 2007.
[Google Scholar]
79.
79. Granlund H, Erkko P, Eriksson E, Reitamo S. Comparison of cyclosporine and topical betamethasone-17,21-dipropionate in the treatment of severe chronic hand eczema. Acta Derm Venereol 1996;76:371-6.
[Google Scholar]
80.
80. Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of atopic eczema- a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2007;21:606-19.
[Google Scholar]
81.
81. Berth-Jones J, Takwale A, Tan E, Barclay G, Agarwal S, Ahmed I. Azathioprine in severe adult atopic dermatitis: A double-blind, placebo-controlled, cross-over trial. Br J Dermatol 2002;147:324-30.
[Google Scholar]
82.
82. Anstey AV, Wakelin S, Reynolds NJ. Guidelines for prescribing azathioprine in dermatology. Br J Dermatol 2004;151:1123-32.
[Google Scholar]
83.
83. Shaffrali FC, Colver GB, Messenger AG, Gawkrodger DJ. Experience with low-dose methotrexate for the treatment of eczema in the elderly. J Am Acad Dermatol 2003;48:417-9.
[Google Scholar]
84.
84. Pickenaker A, Luger TA, Schwarz T. Dyshidrotic eczema treated with mycophenolate mofetil. Arch Dermatol 1998;134:378-9.
[Google Scholar]
85.
85. Molin S, Vollmer S, Weiss EH, Ruzicka T, Prinz JC. Filaggrin mutations may confer susceptibility to chronic hand eczema characterized by combined allergic and irritant contact dermatitis. Br J Dermatol 2009;161:801-7.
[Google Scholar]

Fulltext Views
1722

PDF downloads
283
Show Sections